Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Cell atlas cracks open ‘black box’ of mammalian spinal cord development
The atlas details the genetics, birth dates and gene-expression signatures of roughly 150 neuron subtypes in the dorsal horn of the mouse spinal cord.
Cell atlas cracks open ‘black box’ of mammalian spinal cord development
The atlas details the genetics, birth dates and gene-expression signatures of roughly 150 neuron subtypes in the dorsal horn of the mouse spinal cord.
Pangenomic approaches to the genetics of autism, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 2 February.
Pangenomic approaches to the genetics of autism, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 2 February.
Betting blind on AI and the scientific mind
If the struggle to articulate an idea is part of how you come to understand it, then tools that bypass that struggle might degrade your capacity for the kind of thinking that matters most for actual discovery.
Betting blind on AI and the scientific mind
If the struggle to articulate an idea is part of how you come to understand it, then tools that bypass that struggle might degrade your capacity for the kind of thinking that matters most for actual discovery.